Navigation Links
Avastin Added to Chemo Helps Women With Advanced Breast Cancer
Date:5/31/2008

Anti-angiogenesis drug prolonged progression-free survival, study finds

SATURDAY, May 31 (HealthDay News) -- Adding the drug Avastin to chemotherapy lengthened progression-free survival in women with advanced breast cancer, new research shows.

Previous studies have found that adding Avastin (bevacizumab) to the chemotherapy drug Taxol (paclitaxel) in women with advanced breast cancer actually doubled progression-free survival.

Avastin is already approved for use in metastatic colon cancer, non-small cell lung cancer and, recently, in newly diagnosed metastatic breast cancer (in combination with paclitaxel).

"Avastin is an anti-angiogenesis drug [one that inhibits blood supply to the tumor] that appears to have activity across a variety of cancers," Dr. Nancy Davidson, director of the breast cancer program at Johns Hopkins Kimmel Cancer Center in Baltimore and president of the American Society of Clinical Oncology (ASCO), said during a teleconference earlier this month.

"Angiogenesis is clearly a very important process in the tumorogenesis of many malignances, and one of the first agents we've had available to us in the clinic is Avastin, which has demonstrated some efficacy in several genotypes," said study author Dr. David Miles, a medical oncologist at the Mount Vernon Cancer Centre in Middlesex, U.K.

Miles, who is presenting the findings this weekend at the American Society for Clinical Oncology annual meeting in Chicago, spoke at a Saturday news conference.

The current study looked at Avastin added to the chemotherapy agent Taxotere (docetaxel). Taxotere is more commonly used outside the United States, while Taxol is more commonly used in the United States.

This phase III trial involved 736 patients randomized into one of three groups: Taxotere alone, Taxotere plus a high dose (15 mg/kg) of Avastin, or Taxotere plus a low dose of Avastin (7.5 mg/kg). The lower dose of Avastin is the current standard dose for breast cancer treatment, while the higher dose is the standard dose for colon cancer.

After a median follow-up of almost one year, women taking the lower dose of Avastin were 21 percent less likely and those taking the higher dose 28 percent less likely to have a recurrence compared to those receiving chemo alone. More than half (55.2 percent) in the low-dose group and two-thirds (63.3 percent) in the high-dose group saw their tumors shrink, compared to 44.4 percent in the placebo group.

Patients receiving Avastin did have more severe side effects (74 percent to 75 percent versus 67 percent in the chemotherapy-alone group).

Final data on overall survival is not yet available. According to Dr. Eric Weiner, director of the breast oncology center at Dana-Farber Cancer Institute in Boston and moderator of the Saturday news conference, "it is unlikely there will be a survival benefit."

The U.S. Food and Drug Administration tends to approve second and third-line drugs based on progression-free survival and drugs for the first-line setting on survival, Weiner said, adding that he "personally does not understand that approach."

Progression-free survival can be seen as a quality-of-life improvement. "Having the disease under control for longer, as long as the toxicity of treatment is not substantial, is something that is well worth it," Weiner said. "So a drug that can substantially improve profession-free survival is a drug that can at least, in some patients, make their lives that much better while they are dealing with this illness."

More information

The American Society of Clinical Oncology has more information on breast cancer.



SOURCES: May 31, 2008, news conference with Eric Weiner, M.D., director, breast oncology center, Dana-Farber Cancer Institute, Boston; David Miles, M.D., medical oncologist, Mount Vernon Cancer Centre, Middlesex, U.K.; May 6, 2008, teleconference with Nancy Davidson, M.D., director, breast cancer program, Johns Hopkins Kimmel Cancer Center, Baltimore, and president, American Society of Clinical Oncology; May 31, 2008, presentations, American Society of Clinical Oncology annual meeting, Chicago


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Panel Says No to Avastin for Advanced Breast Cancer
2. Taxol with avastin produces noteworthy results
3. Many More Patients Can Now Benefit from Avastins Proven Survival Benefits
4. Despite Oncologists Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
5. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
6. FDA OKs Avastin for Advanced Breast Cancer
7. Off-Label Avastin Use for Wet Macular Degeneration
8. Avastin Added to Chemo Helps Women With Advanced Cancer
9. Corals added to IUCN Red List of Threatened Species for first time
10. Halozyme Therapeutics Added to Nasdaq Biotech Index
11. Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Avastin Added to Chemo Helps Women With Advanced Breast Cancer
(Date:5/25/2016)... ... May 25, 2016 , ... Conrad ... annual Medical and Prescription Drug survey , an employee benefits ... which was conducted in December 2015, indicates that employers are turning to consumer ...
(Date:5/25/2016)... ... ... America Walks , a national advocacy organization that promotes walking and walkable ... Graduate School of Public Health , has been awarded a Walking College ... the country to participate in a four-month training program designed to strengthen local efforts ...
(Date:5/25/2016)... ... 25, 2016 , ... Laser Skin & Wellness Center is excited ... time of female aging. The Julietâ„¢ procedure helps to reverse the ... leakage, laxity, itchiness and pain have reported real relief from these and other problems ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... insurance, has seen a significant spike in their clients' employee participation for their ... biometric health screening by implementing a high-deductible health plan with outcome-based deductible incentives. ...
(Date:5/25/2016)... ... ... Consumer access to organic foods and grower access to food processers is ... cereals and other plant-based foods, will introduce the first consumer product (a new breakfast ... Hesco/Dakota Organic Products. , The transitional designation means the cereal was made using at ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... Dutch surgeons have launched a ground-breaking medical app to help doctors ... a global scale. Medical professionals from Europe , ... the US have already signed up for the app, which combines ... environment. Education  "Imagine a doctor for Medicines ... at Harvard to treat a bomb victim via live streaming - ...
(Date:5/23/2016)... -- Global Paclitaxel Market 2016 Industry Research ... and the Paclitaxel analysis in this study is supported ... its players. This is the latest Paclitaxel ... current state of the industry while providing a basic ... industry chain structure. The Paclitaxel market analysis is provided ...
(Date:5/23/2016)... NEW YORK , May 23, 2016 /PRNewswire/ ... Mass Spectrometry Market Size, Share, Development, Growth and ... Platform (Hybrid, Single and Other), by Application (Drug ... Others), by End Users (Pharmaceuticals, Life Science and ... Published by P&S Market Research, the global ...
Breaking Medicine Technology: